Five start-ups selected for the second funding phase of the Co-Innovation Program with Singapore – Charité partners wanted

Within the, Co-innovation program between Enterprise Singapore and Charité/BIH, numerous start-ups from Singapore have expressed their interest in collaboration. From the submitted Expressions of Interest, five companies have been selected to move forward into the second funding phase.

The selected start-ups represent a broad range of innovative approaches:

• Histoindex – MASH RPI: AI-powered tool for analyzing liver biopsies in MASH patients, supporting individualized risk assessment. Category: Digital Pathology / AI Diagnostics
• Biosense Diagnostics – Puffinder: Medical device for safe placement of nasogastric tubes, usable in hospitals and home care. Category: Medical Device / Diagnostics
• Kyan Technologies – Optim.AI: Combines AI and biological testing to identify optimal cancer therapies. Category: Cancer Diagnostics / Therapy Selection
• Conex Health – PreSAGE: Non-invasive, AI-based monitoring solution for fall prevention in high-risk patients. Category: Patient Monitoring / Fall Prevention
• Enigma Health – Enigma AI Platform: On-premises AI solution automating complex healthcare workflows with a focus on compliance and data security. Category: Generative AI / Workflow Automation

Further information about the start-ups can be found here.

For these projects, clinical and scientific partners at Charité and BIH are now being sought to jointly advance the concepts – from pilot projects and validation studies to co-development of new products.

👉 Interested researchers can contact CBI until the end of November 2025 to get to know one of the start-ups. If there is mutual interest in collaboration, a Letter of Intent (LoI) can then be issued.
This collaboration offers the opportunity to bring new biomedical technologies into application in close cooperation with international start-ups – thereby creating translational value for patients in Germany and worldwide.